Inhaler testing equipment company Copley Scientific has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as an associate member, the company said.
According to IPAC-RS, “A corporation is eligible for participation in IPAC-RS initiatives as an associate member if it develops or manufactures components and/or devices for orally inhaled and nasal drug products (OINDP) or provides scientific or technical services relating to development and manufacture of OINDP.”
As one of 8 associate member companies, Copley Scientific said, it plans to “actively participate in consortium working groups and knowledge networks, drawing on expertise accrued over decades working at the forefront of inhaler testing equipment development.”
Copley Scientific Director Mark Copley commented, “IPAC-RS plays a vital role in initiating and driving collaboration across the industry and we are looking forward to contributing to its work. Pulmonary drug delivery is uniquely complex and there remain considerable challenges for the community to address. A particular area of interest for us is the ongoing evolution of the test methods associated with delivered dose uniformity and aerodynamic particle size distribution measurements. These metrics define OINDP performance and are measured from R&D through to QC. Ensuring the associated methods and equipment are relevant, precise, and robustly fit-for-purpose is therefore crucial.”
IPAC-RS Chair Robert Berger said, “IPAC-RS welcomes Copley as an Associate Member. From our earliest days as a consortium, we have appreciated the perspectives and engagement of our supplier members and we look forward to Copley’s involvement.”
Read the Copley Scientific press release.
